Dr. Garcia-Manero, an expert on myelodysplastic syndromes, discusses this group of disorders representing a misunderstood and often ignored type of blood cancer. He explains everything from risk factors to early symptoms and treatment options.
Unmet Needs of Individuals Living with Higher-Risk Myelodysplastic Syndromes: Perspectives from the Global Patient Advocacy Community
FDA Approvals, News & UpdatesMyelodysplastic Syndromes
On July 7, 2020, the FDA approved Inqovi (decitabine plus cedazuridine; from Astex Pharmaceuticals and Taiho Oncology) tablets for the treatment of adults with intermediate- or high-risk myelodysplastic syndromes, or MDS, including patients with chronic myelomonocytic leukemia. Inqovi is an orally administered fixed-dose combination of the hypomethylating agent decitabine plus the cytidine deaminase inhibitor cedazuridine.
From Your NavigatorMyelodysplastic Syndromes
By Stephen Mazer, MSN, RN-BC, OCN, ONN-CGStephen Mazer, MSN, RN-BC, OCN, ONN-CG, Veronica Campos, DNP, MSN, RN, NE-BC, OCN
Myelodysplastic syndromes are a group of cancers that affect immature blood cells in the bone marrow. Two oncology navigators explain the risk factors and current treatment options available for patients diagnosed with this type of malignancy.
Results 1 - 5 of 5